过氧化物酶体增殖物活化受体γ

过氧化物酶体增殖物活化受体γ
	PPAR-G dimer bound to DNA. PDB rendering based on 3e00[1].
有效结构
PDB	直系同源检索：PDBe, RCSB
PDB查询代码列表
	1FM6, 1FM9, 1I7I, 1K74, 1KNU, 1NYX, 1PRG, 1RDT, 1WM0, 1ZEO, 1ZGY, 2ATH, 2F4B, 2FVJ, 2G0G, 2G0H, 2GTK, 2HFP, 2HWQ, 2HWR, 2I4J, 2I4P, 2I4Z, 2OM9, 2P4Y, 2POB, 2PRG, 2Q59, 2Q5P, 2Q5S, 2Q61, 2Q6R, 2Q6S, 2Q8S, 2QMV, 2VSR, 2VST, 2VV0, 2VV1, 2VV2, 2VV3, 2VV4, 2XKW, 2YFE, 2ZK0, 2ZK1, 2ZK2, 2ZK3, 2ZK4, 2ZK5, 2ZK6, 2ZNO, 2ZVT, 3ADS, 3ADT, 3ADU, 3ADV, 3ADW, 3ADX, 3AN3, 3AN4, 3B0Q, 3B0R, 3B1M, 3B3K, 3BC5, 3CDP, 3CDS, 3CS8, 3CWD, 3D6D, 3DZU, 3DZY, 3E00, 3ET0, 3ET3, 3FEJ, 3FUR, 3G9E, 3GBK, 3H0A, 3HO0, 3HOD, 3IA6, 3K8S, 3KMG, 3LMP, 3NOA, 3OSI, 3OSW, 3PBA, 3PO9, 3PRG, 3QT0, 3R5N, 3R8A, 3R8I, 3S9S, 3SZ1, 3T03, 3TY0, 3U9Q, 3V9T, 3V9V, 3V9Y, 3VJH, 3VJI, 3VN2, 3VSO, 3VSP, 4A4V, 4A4W, 4E4K, 4E4Q, 4EM9, 4EMA, 4F9M, 4FGY, 4PRG
标识
代号	PPARG; CIMT1; GLM1; NR1C3; PPARG1; PPARG2; PPARgamma
扩展标识	遗传学：601487 鼠基因：97747 同源基因：7899 IUPHAR: ChEMBL: 235 GeneCards: PPARG Gene
基因本体论描述
分子功能	· RNA polymerase II regulatory region DNA binding; · DNA binding; · chromatin binding; · sequence-specific DNA binding transcription factor activity; · steroid hormone receptor activity; · ligand-activated sequence-specific DNA binding RNA polymerase II transcription factor activity; · prostaglandin receptor activity; · protein binding; · drug binding; · zinc ion binding; · enzyme binding; · ligand-dependent nuclear receptor transcription coactivator activity; · activating transcription factor binding; · sequence-specific DNA binding; · transcription regulatory region DNA binding; · retinoid X receptor binding; · arachidonic acid binding;
细胞成分	· nucleus; · nucleoplasm; · cytosol;
生物过程	· negative regulation of transcription from RNA polymerase II promoter; · placenta development; · negative regulation of acute inflammatory response; · transcription initiation from RNA polymerase II promoter; · lipid metabolic process; · induction of apoptosis; · activation of cysteine-type endopeptidase activity involved in apoptotic process; · signal transduction; · heart development; · response to nutrient; · regulation of blood pressure; · response to cold; · gene expression; · negative regulation of macrophage derived foam cell differentiation; · negative regulation of receptor biosynthetic process; · negative regulation of cholesterol storage; · negative regulation of sequestering of triglyceride; · long-chain fatty acid transport; · fatty acid oxidation; · monocyte differentiation; · negative regulation of cell growth; · epithelial cell differentiation; · response to caffeine; · organ regeneration; · response to retinoic acid; · cellular response to insulin stimulus; · response to vitamin A; · response to lipid; · peroxisome proliferator activated receptor signaling pathway; · response to drug; · glucose homeostasis; · lipoprotein transport; · response to estrogen stimulus; · innate immune response; · cell fate commitment; · positive regulation of fat cell differentiation; · low-density lipoprotein particle receptor biosynthetic process; · negative regulation of transcription, DNA-dependent; · positive regulation of transcription, DNA-dependent; · positive regulation of transcription from RNA polymerase II promoter; · positive regulation of fatty acid oxidation; · cell maturation; · negative regulation of smooth muscle cell proliferation; · positive regulation of oligodendrocyte differentiation; · white fat cell differentiation; · brown fat cell differentiation; · positive regulation of sequence-specific DNA binding transcription factor activity; · negative regulation of telomerase activity; · lipid homeostasis; · response to low-density lipoprotein particle stimulus; · negative regulation of interferon-gamma-mediated signaling pathway; · regulation of cholesterol transporter activity; · cellular response to lithium ion;
	Sources: Amigo / QuickGO
RNA表达模式
	更多表达数据
直系同源体

过氧化物酶体增殖物活化受体γ（Peroxisome proliferator-activated receptor gamma ，缩写为PPAR-γ或PPARG），也称胰島素增敏劑受体（glitazone receptor），或 NR1C3（意为核受体第一亚科C集团第3号，nuclear receptor subfamily 1, group C, member 3）是一种位于人类染色体上的二型核受体，由PPARG基因编码。[2][3][4]对脂肪细胞和胰岛素有重要的作用，是治疗糖尿病的研究对象之一。[5]

来源

Vikas Chandra, Pengxiang Huang, Yoshitomo Hamuro, Srilatha Raghuram, Yongjun Wang, Thomas P. Burris, Fraydoon Rastinejad. . Nature. 2008-11-20, 456 (7220): 350–356 [2019-05-26]. ISSN 1476-4687. PMC 2743566 . PMID 19043829. doi:10.1038/nature07413.
Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, Hsieh L, Greene G, Nimer SD. . Gene Expr. 1995, 4 (4-5): 281–99. PMID 7787419.
Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz M, Moller DE, Berger J. . Biochem. Biophys. Res. Commun. July 1996, 224 (2): 431–7. PMID 8702406. doi:10.1006/bbrc.1996.1044.
Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W. . Pharmacol. Rev. December 2006, 58 (4): 726–41. PMID 17132851. doi:10.1124/pr.58.4.5.
刘英姿 ,刘昭前 , 周宏灏. (PDF). 中国临床药理学杂志. 2007, 23 (4): 308–310. 1001-6821(2007)04-0308-03 （中文）.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Vikas Chandra, Pengxiang Huang, Yoshitomo Hamuro, Srilatha Raghuram, Yongjun Wang, Thomas P. Burris, Fraydoon Rastinejad. . Nature. 2008-11-20, 456 (7220): 350–356 [2019-05-26]. ISSN 1476-4687. PMC 2743566 . PMID 19043829. doi:10.1038/nature07413.

[pmid7787419-2] Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, Hsieh L, Greene G, Nimer SD. . Gene Expr. 1995, 4 (4-5): 281–99. PMID 7787419.

[pmid8702406-3] Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz M, Moller DE, Berger J. . Biochem. Biophys. Res. Commun. July 1996, 224 (2): 431–7. PMID 8702406. doi:10.1006/bbrc.1996.1044.

[pmid17132851-4] Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W. . Pharmacol. Rev. December 2006, 58 (4): 726–41. PMID 17132851. doi:10.1124/pr.58.4.5.

[5] 刘英姿 ,刘昭前 , 周宏灏. (PDF). 中国临床药理学杂志. 2007, 23 (4): 308–310. 1001-6821(2007)04-0308-03 （中文）.